A Mission for Making Good Medicine The University of Tennessee Research Foundation (UTRF), the University of Tennessee Health Science Center (UTHSC), and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel treatment with promising efficacy against pancreatic cancer tumors. According to the Genetic and Rare Diseases Information Center, the total number of (read more)
License Agreement
UTRF Startup Developing Next-Generation Devices for Endoscopy
A technology from the University of Tennessee, Knoxville, lies at the heart of a startup company creating next-generation medical devices for flexible endoscopy. EndoTheia harnesses the power of intelligently micro-machined materials to create highly dexterous manipulators, adding flexibility that increases therapeutic yields in complex endoscopic procedures. The company’s devices supplement widely used and commercially available (read more)
UTRF Licensee Announces Positive Phase 2 Clinical Results of VERU-111 for COVID-19
UTRF licensee Veru, Inc. announced today significant potential of VERU-111 in treating COVID-19, both as a broad-spectrum antiviral and an anti-inflammatory agent, which may help prevent effects leading to Acute Respiratory Distress Syndrome. Statistically significant data from the Phase 2 clinical study results show an 81% relative reduction in death or respiratory failure at Day (read more)